Document Classification

Section Type: RESULTS

Text: At 24 weeks, greater improvements in adjusted mean change from baseline HbA1c (difference vs placebo [95 % CI], -0. 33 % [-0. 50 %, -0. 17 %], [-4 (-5. 5, -1. 9) mmol/mol], P < 0. 0001), FPG (-0. 41 [-0. 78, -0. 03] mmol/L, P = 0. 03), PPG AUC0-180 (-168 [-245, -91. 8] mmol min/L, P < 0. 0001), C-peptide AUC0-180 (19. 7 [5. 2, 34. 2] nmol min/L, P = 0. 008), insulinogenic index (0. 06 % [0. 02 %, 0. 09 %], P = 0. 002), and greater suppression of glucagon secretion (glucagon AUC0-180, -322 [-493. 6, -150. 7] pmol min/L, P = 0. 0003) were observed with saxagliptin versus placebo.